UroGen Pharma Ltd. (URGN)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 16.97 |
| Open | 17.04 |
| Bid | 16.76 x 200 |
| Ask | 16.85 x 200 |
| Day's range | 16.74 - 17.25 |
| 52-week range | 8.69 - 24.13 |
| Volume | |
| Avg. volume | 597,217 |
| Market cap | 690.163M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investor's Business Daily
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday. IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
- Zacks
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Investor's Business Daily
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
UroGen stock rocketed Thursday on "unprecedented" test results for its bladder cancer treatment, a gel-based drug that avoids surgery.
© 2024 Yahoo. All rights reserved.